autophagy related 2BGenealiases: BLTP4B · C14orf103
Q-omics provides the consensus-scored ATG2B profile across patient tissues and cancer cell-line models. ATG2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATG2B is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ATG2B protein abundance shows 32,727 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where ATG2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATG2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATG2B survival associations across molecular data types. ATG2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (12) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATG2B RNA expression–survival associations across cancer types. High ATG2B expression shows unfavorable associations in UVM, ACC, LUSC and BLCA, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATG2B RNA expression.
This table summarizes ATG2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ATG2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATG2B shows lower tumor expression in THCA, KIRC, LUAD, BRCA and KICH and higher tumor expression in HNSC. The THCA box plot shows higher ATG2B RNA expression in normal versus tumor tissue (log2 FC = −0.780, t-test p < 0.001).
This table shows molecular features associated with ATG2B in patient tissues and cancer cell lines. In patient samples, ATG2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATG2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
